Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.49 |
| ▸ | PRCP | P42785 | 3/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18085727 | 1.00 | TSHR (0.65) | TSHRNPSR1OPRM1OPRK1GID4 | |
| SCHEMBL31569203 | 1.00 | TSHR (0.65) | TSHRNPSR1OPRM1OPRK1GID4 | |
| SCHEMBL18085742 | 1.00 | TSHR (0.65) | TSHRNPSR1OPRM1OPRK1GID4 | |
| Hydrochloric Acid SCHEMBL19953653 | 0.98 | TSHR (0.68) | TSHRNPSR1OPRM1OPRK1GID4 | |
| Hydrochloric Acid SCHEMBL1149802 | 0.98 | TSHR (0.68) | TSHRNPSR1OPRM1OPRK1GID4 | |
| SCHEMBL26998916 | 0.84 | TSHR (0.44) | TSHRNPSR1OPRM1OPRK1SLC6A2 | |
| SCHEMBL4143242 | 0.84 | TSHR (0.44) | TSHRNPSR1OPRM1OPRK1SLC6A2 | |
| SCHEMBL23119015 | 0.84 | TSHR (0.60) | TSHRNPSR1OPRM1OPRK1PRCP | |
| SCHEMBL30442509 | 0.84 | TSHR (0.60) | TSHRNPSR1OPRM1OPRK1GID4 | |
| SCHEMBL7694988 | 0.84 | TSHR (0.60) | TSHRNPSR1OPRM1OPRK1GID4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025101780-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | OCTANT, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| EP-3243814-B1 | 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS | ABBVIE INC (US) | 2018-10-17 | — | — | EP | disclosed |
| WO-2018047983-A1 | INDANE DERIVATIVES USEFUL AS MODULATORS OF MGLUR7 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-15 | — | — | WO | disclosed |
| EP-3243814-A1 | 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS | AbbVie Inc. (US) | 2017-11-15 | — | — | EP | disclosed |
| US-9802934-B2 | Process for the synthesis of (R)-praziquantel | TONGLI BIOMEDICAL CO., LTD. (CN) | 2017-10-31 | — | — | US | disclosed |
| EP-2134684-B1 | 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS | ABBVIE INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-9657017-B2 | Crystal form of (R)-praziquantel and preparation method and application thereof | TONGLI BIOMEDICAL CO., LTD. (CN) | 2017-05-23 | — | — | US | disclosed |
| US-20170121330-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF (R)-PRAZIQUANTEL | TONGLI BIOMEDICAL CO., LTD (CN) | 2017-05-04 | — | — | US | disclosed |
| US-20160272636-A1 | CRYSTAL FORM OF (R)-PRAZIQUANTEL AND PREPARATION METHOD AND APPLICATION THEREOF | TONGLI BIOMEDICAL CO., LTD (CN) | 2016-09-22 | — | — | US | disclosed |
| US-9359296-B2 | 7-substituted indole Mcl-1 inhibitors | ABBVIE INC. (US) | 2016-06-07 | — | — | US | disclosed |
| WO-2009117283-A2 | QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK & CO., INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| US-20090054402-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2008131000-A2 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | WO | disclosed |
| EP-1857444-A1 | TETRAHYDROISOQUINOLINE COMPOUND AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2007-11-21 | — | — | EP | disclosed |
| EP-1200375-B1 | NITRATION IN A STATIC MICROMIXER | MERCK PATENT GMBH (DE) | 2004-09-22 | — | — | EP | disclosed |
| EP-1200375-A2 | NITRATION IN A STATIC MICROMIXER | MERCK PATENT GmbH (DE) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001009065-A2 | NITRATION IN A STATIC MICROMIXER | MERCK PATENT GMBH (DE) | 2001-02-08 | — | — | WO | disclosed |
| US-4404206-A | HYPOTENSIVE AND CARDIOTONIC AGENTS | SCIENCE UNION ET CIE (FR) | 1983-09-13 | — | — | US | disclosed |
| EP-0049658-A1 | Substituted imino diacids, their preparation and pharmaceutical preparations containing them | ADIR (FR) | 1982-04-14 | — | — | EP | disclosed |
| EP-0031741-A1 | Substituted imino-acids, process for their preparation and their use as enzyme inhibitors | SCIENCE UNION ET Cie SOCIETE FRANCAISE DE RECHERCHE MEDICALE (FR) | 1981-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121330-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF (R)-PRAZIQUANTEL | COASY, CYP3A4, CYP4B1 | TSHR 3824/4885NPSR1 2715/4885OPRM1 1962/4885 |
| US-20160272636-A1 | CRYSTAL FORM OF (R)-PRAZIQUANTEL AND PREPARATION METHOD AND APPLICATION THEREOF | CYP2C9, CYP1A2, CYP4B1 | TSHR 1879/4885NPSR1 2982/4885OPRM1 768/4885 |
| US-20090054402-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, API5 | TSHR 4574/4885NPSR1 4601/4885OPRM1 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.